The FDA has approved a prefilled injection device for adults with polycythemia vera, according to a press release. The ropeginterferon alfa-2b-njft device (BESREMi Pen, PharmaEssentia) allows for self-administration, differentiating it from the currently available prefilled syringe, which previously received FDA approval in 2021. PharmaEssentia expects the pen “to become commercially available